A Prospective Observational Study on BBV152 Coronavirus Vaccine Use in Adolescents and Comparison with Adults: Interim Results of the First Real-World Safety Analysis.

Upinder KaurAnju K LMayank ChauhanAditi JoshiAgniva DasSangeeta KansalVaibhav JaisawalKishor PatwardhanSankha Shubhra Chakrabarti

Published in: Drug safety (2022)

COVAXIN carries an overall favorable short-term safety profile in adolescents. The observed AEFI rates in adolescents are much lower than that reported with mRNA vaccines, but head-head comparisons in the same population are required to generate relative vaccine safety data. Female adolescents and those with a history of allergy need watchfulness for severe and persistent AEFIs. With some AEFIs persisting at 14 days, a longer follow-up is recommended to strengthen the safety data of COVAXIN.

Keyphrases

young adults
physical activity
sars cov
electronic health record
big data
early onset
artificial intelligence